Activities
Naogen Pharma S.A.S, founded in 2016, finalizes the developement of a range of innovative radiopharmaceutical products for PET-Rubidium-82 imaging for nuclear physicians.
Global marketing is scheduled from 2022 following the first marketing authorization (AMM) in cardiology.
PET-Rubidium-82 imaging, which allows precise quantification of microvascularization, is positioned as an innovative disruptive imaging modality that can improve the diagnosis and management of many patients.
